Sheng Xiao

Title: Innovations by Sheng Xiao in Cancer Treatment

Introduction

Sheng Xiao is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of medical research, particularly in the treatment of cancer and infections. With a total of 2 patents, his work is paving the way for new therapeutic approaches.

Latest Patents

One of Sheng Xiao's latest patents is titled "Use of RPL41 to treat infections and inhibit cancer." This invention relates to peptides of RPL41 and their application in treating cancer and microbial infections. The patent contemplates the use of modified forms of RPL41, including substitutional variants and mimetics. It also discusses mono- and combination therapies with other cancer treatments. Another significant patent is "HMGI(Y)-LAMA4* fusion oncogene, oncoprotein and methods of use." This patent describes an oncogene designated HMGI(Y)-LAMA4*, which incorporates a HMGI(Y) domain fused through inversion and translocation to LAMA4*. The molecular characterization of HMGI(Y)-LAMA4* provides nucleic acid sequences and amino acid sequences that are useful for the detection and treatment of certain tumors.

Career Highlights

Sheng Xiao is affiliated with The Brigham and Women's Hospital, Inc., where he conducts his research and develops his innovative ideas. His work is instrumental in advancing the understanding of cancer biology and therapeutic strategies.

Collaborations

One of his notable collaborators is Jonathan A. Fletcher, who works alongside him in the research endeavors at The Brigham and Women's Hospital.

Conclusion

Sheng Xiao's contributions to cancer treatment through his innovative patents highlight the importance of research in developing new therapies. His work continues to inspire advancements in medical science and patient care.